|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C7H15Cl2N2O2P |
|||
| Molecular Weight | 261.09 | CAS No. | 50-18-0 | |
| Solubility (25°C)* | In vitro | DMSO | 52 mg/mL (199.16 mM) | |
| Ethanol | 52 mg/mL (199.16 mM) | |||
| Water | 43 mg/mL (164.69 mM) | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Cyclophosphamide(NSC 26271,Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cytophosphane) is a nitrogen mustard alkylating agent from the oxazophorines group. | |
|---|---|---|
| Targets |
|
|
| In vivo | Cyclophosphamide is an alkylating agent with cytotoxic and immunosuppressive activities. Cyclophosphamide requires enzymatic and chemical activation to release active phosphoramide mustard which produces the interstrand and intrastrand DNA crosslinks at guanine N-7 positions. Cyclophosphamide exerts its cytotoxic activity by inhibiting nuclear DNA replication. The mechanism of Cyclophosphamide -induced immunosuppression is possibly due to direct cytotoxic effect of the drug on immunocompetent lymphocytes, particulafly those that have undergone antigenic differentiation and division. Cyclophosphamide has its greatest effect on B cells with relative T cell-sparing effect. [1] Trials in various tumor-bearing animals confirmed this in vivo activity and demonstrated fairly potent antitumor effect. Cyclophosphamide, in combination with other antineoplastic agents, is used for the treatment of various cancers, including breast, lymphoid and pediatric malignancies. [2] |
Protocol (from reference)
References
|
Customer Product Validation
-
Data from [Data independently produced by Cancer Res, 2012, 72(23):6200-8]
Selleck's Cyclophosphamide has been cited by 10 publications
| Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host [ J Immunother, 2024, 10.1097/CJI.0000000000000505] | PubMed: 38270462 |
| Exploring miRNA‑target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy [ Oncol Lett, 2024, 27(4):158] | PubMed: 38426156 |
| ATR/Chk1 interacting lncRNA modulates DNA damage response to induce breast cancer chemoresistance [ Cell Insight, 2024, 3(5):100183] | PubMed: 39148723 |
| Adipose-derived stem cells promote the repair of chemotherapy-induced premature ovarian failure by inhibiting granulosa cells apoptosis and senescence [ Stem Cell Res Ther, 2023, 14(1):75] | PubMed: 37038203 |
| PTC596-Induced BMI-1 Inhibition Fights Neuroblastoma Multidrug Resistance by Inducing Ferroptosis [ Antioxidants (Basel), 2023, 13(1)3] | PubMed: 38275623 |
| Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy [ Neoplasia, 2023, 10.1016/j.neo.2023.100949] | PubMed: 37956532 |
| Novel model of triple-negative breast cancer produces viable circulating tumor cells and rapid lung metastasis for functional testing in vivo [ Neoplasma, 2023, 10.4149/neo_2023_230404N185] | PubMed: 37789779 |
| Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents [ BMC Pregnancy Childbirth, 2023, 23(1):151] | PubMed: 36890528 |
| Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents [ BMC Pregnancy Childbirth, 2023, 23(1):151] | PubMed: 36890528 |
| Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. [Markant SL, et al. Cancer Res, 2013, 73(20):6310-22] | PubMed: 24067506 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.